

# Neuroimmunology: Reference List

(anti-Ganglioside and -MAG Antibody ELISA tests by BÜHLMANN in the Literature)



## IVDR Compliant

(anti-MAG and -Ganglioside Antibodies)

## 100+ References

The literature list contains articles in which the IVDD version of BÜHLMANN GanglioCombi® products have been used.

### BÜHLMANN GanglioCombi® - over 25 References

**Germano F et al., 2022:** COVID-19 vaccine-related Guillain-Barré syndrome in the Liguria region of Italy: A multicenter case series. *J Neurol Sci* **440**: 120330  
DOI: [10.1016/j.jns.2022.120330](https://doi.org/10.1016/j.jns.2022.120330) PMID: **35802961**

**Mussinato I et al., 2022:** Possible association between Guillain-Barré syndrome and SARS-CoV-2 infection in children: A case report and literature review. *Exp Ther Med* **24(1)**: 462  
DOI: [10.3892/etm.2022.11389](https://doi.org/10.3892/etm.2022.11389)

**Peillet C et al., 2022:** Anti-disialosyl-immunoglobulin M chronic autoimmune neuropathies: a nationwide multicenter retrospective study. *Eur J Neurol* **29(12)**: 3547-3555  
DOI: [10.1111/ene.15523](https://doi.org/10.1111/ene.15523)

**Rumsey J W et al., 2022:** Classical Complement Pathway Inhibition in a „Human-On-A-Chip“ Model of Autoimmune Demyelinating Neuropathies. *Adv Ther (Weinh)* **5(6)**: 2200030  
DOI: [10.1002/adtp.200200030](https://doi.org/10.1002/adtp.200200030)

**Aljaafari D et al., 2021:** Miller Fisher Variant of Guillain-Barré Syndrome Triggered by Ventilator-Associated Pneumonia. *Int Med Case Rep J* **14**: 339-342  
DOI: [10.2147/IMCRJ.S309831](https://doi.org/10.2147/IMCRJ.S309831)

**Ravlic M M et al., 2021:** Ocular Manifestations of Miller Fisher Syndrome: a Case Report. *Med Arch* **75(3)**: 234-236  
DOI: [10.5455/medarh.2021.75.234-236](https://doi.org/10.5455/medarh.2021.75.234-236)

**Civardi C et al., 2020:** Antiganglioside antibodies in Guillain-Barré syndrome associated with SARS-CoV-2 infection. *J Neurol Neurosurg Psychiatry* **28 August, 2020**  
DOI: [10.1136/jnnp-2020-324279](https://doi.org/10.1136/jnnp-2020-324279) PMID: **32859744**

**Garnero M et al., 2020:** COVID-19-related and not related Guillain-Barré syndromes share the same management pitfalls during lock down: The experience of Liguria region in Italy. *Neurol Sci* **418**: 117114  
DOI: [10.1016/j.jns.2020.117114](https://doi.org/10.1016/j.jns.2020.117114)

**Toscano G et al., 2020:** Guillain-Barré Syndrome Associated with SARS-CoV-2 (Letter to the editor). *NEJM*; **April 27, 2020**  
DOI: [10.1056/NEJMc2009191](https://doi.org/10.1056/NEJMc2009191)

**Choi K-D et al., 2019:** Characteristics of a single oculomotor nerve palsy associated with anti-GQ1b antibody. *J Neurol* **266**: 476-479  
DOI: [10.1007/s00415-018-9161-8](https://doi.org/10.1007/s00415-018-9161-8)

**Delmont E et al., 2019:** Relevance of anti-HNK-1 Antibodies in the management of anti-MAG neuropathies. *J Neurol*; published online **14 May, 2019**  
DOI: [10.1007/s00415-019-09367-0](https://doi.org/10.1007/s00415-019-09367-0)

**Lee S U et al., 2019:** Anti-ganglioside antibody associated acute unilateral vestibulopathy. *J Neurol* **266(1)**: 250-252  
DOI: [10.1007/s00415-018-9109-z](https://doi.org/10.1007/s00415-018-9109-z)

**Yoon L et al., 2019:** Clinical characterization of anti-GQ1b antibody syndrome in Korean children.

J Neuroimmunology **15(330)**: 170-173

DOI: [10.1016/j.jneuroim.2019.01.003](https://doi.org/10.1016/j.jneuroim.2019.01.003)

**Franciotta D et al., 2018:** Anti-ganglioside antibodies: experience from the Italian Association of Neuroimmunology external quality assessment scheme. Clin Chem Lab Med **56(11)**: 1921-1925

DOI: [10.1515/cclm-2018-0234](https://doi.org/10.1515/cclm-2018-0234)

**Sohn S Y and Kim J K, 2018:** Neutropenia Following Intravenous Immunoglobulin Administration in a Patient with Multifocal Motor Neuropathy with Conduction Block. J Neurol Neurophysiol **8**: 409.

DOI: [10.4172/2155-9562.1000409](https://doi.org/10.4172/2155-9562.1000409)

**Anaya J-M et al., 2017:** A comprehensive analysis and immunobiology of autoimmune neurological syndromes during the Zika virus outbreak in Cúcuta, Colombia. Journal of Autoimmunity **77**: 123-138

DOI: [10.1016/j.jaut.2016.12.007](https://doi.org/10.1016/j.jaut.2016.12.007)

**Han T H et al., 2017:** Transient Lower Bulbar Palsy with Elevated Serum anti-GM1 and Anti-GD1b Antibodies during Aripiprazole Treatment. Pediatr Neurol **66**: 96-99

DOI: [10.1016/j.pediatrneurol.2016.07.011](https://doi.org/10.1016/j.pediatrneurol.2016.07.011)

**Herrendorff R et al., 2017:** Selective in vivo removal of pathogenic anti-MAG autoantibodies, an antigen specific treatment option for anti-MAG neuropathy. PNAS May 2, 2017 **114(18)**: E3689-E3698

DOI: [10.1073/pnas.1619386114](https://doi.org/10.1073/pnas.1619386114)

**Legast G M et al., 2017:** Guillain-Barré and Miller Fisher Overlap Syndrome Mimicking Alimentary Botulism.

J Clin Neurol **13(4)**: 442-443

DOI: [10.3988/jcn.2017.13.4.442](https://doi.org/10.3988/jcn.2017.13.4.442)

**Cao-Lormeau V M et al., 2016:** Guillain-Barré Syndrome outbreak associated with Zika virus infection in French Polynesia: a case-control study. Lancet **387** (10027): 1531-1539 (incl. supplement)

DOI: [10.1016/S0140-6736\(16\)00562-6](https://doi.org/10.1016/S0140-6736(16)00562-6)

**Spatola M et al., 2016:** Serum and CSF GQ1b antibodies in isolated ophthalmologic syndromes.

Neurology **86**: 1780-1784

DOI: [10.1212/WNL.0000000000002558](https://doi.org/10.1212/WNL.0000000000002558)

**Kollewe K et al., 2015:** Anti-Ganglioside Antibodies in Amyotrophic Lateral Sclerosis Revisited.

PLoS One, **10(4)**: e0125339

DOI: [10.1371/journal.pone.0125339](https://doi.org/10.1371/journal.pone.0125339)

#### Posters:

**Eckhardt V et al., 2023:** GanglioCombi, a unique standardized multiparametric ELISA for the specific detection of anti-neural antibodies compliant with the new regulatory IVDR standards.

Poster presented at “16<sup>th</sup> Dresden Symposium on Autoimmunity”, Dresden (GE)

**Eckhardt V et al., 2023:** Measuring A Case Series With A Unique Commercially Available Anti-Ganglioside Antibodies ELISA.

Poster presented at “Peripheral Nerve Society” (PNS) Annual Meeting, Copenhagen (DK)

**Eckhardt V et al., 2023:** Unique Commercially Available Multiparametric Anti- Ganglioside Antibodies ELISA Complying With New Regulatory IVDR Standards.

Poster presented at “Peripheral Nerve Society” (PNS) Annual Meeting, Copenhagen (DK)

**Delmont E et al., 2017:** Value of anti-HNK-1 Antibodies in anti-MAG Neuropathies: an analysis of 144 sera.

Poster presented at **2017** “Peripheral Nerve Society” (PNS) Annual Meeting, Sitges (ES)

**Chalah M A et al., 2016:** A comparison of four commercial tests for detecting anti-ganglioside antibodies in patients with well-characterized dysimmune peripheral neuropathies.

Poster presented at “International Congress on Autoimmunity”, Leipzig (GE)

**Mani B et al., 2010:** The Frequency of anti-Ganglioside Antibodies in Blood Donors Compared to Control Groups and Guillain-Barré Syndrome Patients.

Poster presented at “10<sup>th</sup> Dresden Symposium on Autoantibodies”, Dresden (GE)

**Wurster U et al., 2009:** Ganglioside Antibodies in Amyotrophic Lateral Sclerosis.

Poster presented at “9<sup>th</sup> Dresden Symposium on Autoantibodies”, Dresden (GE)

## Further literature citing anti-Ganglioside Antibody ELISA IVD tests by BÜHLMANN

**Kenina V et al., 2015:** Clinical Impact and Relevance of Antiganglioside Antibodies Test Results. Proc. Latvian Acad. Sci., Section B, **69(5)**: 223-227  
DOI: [10.1515/prolas-2015-0033](https://doi.org/10.1515/prolas-2015-0033)

**Uysalol M et al., 2013:** A Rare Form of Guillain-Barré Syndrome: A Child Diagnosed with Anti-GD1a and Anti-GD1b Positive Pharyngeal-Cervical-Brachial Variant. Balkan Med J **30**: 337-341  
DOI: [10.5152/balkanmedj.2013.8334](https://doi.org/10.5152/balkanmedj.2013.8334)

**Lei T et al., 2012:** Anti-ganglioside antibodies were not detected in human subjects infected with or vaccinated against 2009 pandemic influenza A (H1N1) virus. Vaccine **30**: 2605-2610  
DOI: [10.1016/j.vaccine.2012.02.009](https://doi.org/10.1016/j.vaccine.2012.02.009)

**Sharma M B et al., 2011:** The presence of Mycoplasma pneumoniae infection and GM1 ganglioside antibodies in Guillain-Barré syndrome. J Infect Dev Countries **5(6)**: 459-464  
DOI: [10.3855/jidc.1508](https://doi.org/10.3855/jidc.1508)

## anti-MAG Antibodies ELISA IVD test by BÜHLMANN - over 75 References

**Briani C et al., 2023:** Vasculitic flare in a patient with anti-myelin-associated glycoprotein (MAG) antibody following mRNA-1273 SARS-CoV-2 vaccine. J Neurol **270(3)**: 1207-1210  
DOI: [10.1007/s00415-022-11452](https://doi.org/10.1007/s00415-022-11452)

**Castellani F et al., 2023:** Mutational Profile in 75 Patients With Anti-Myelin-Associated Glycoprotein Neuropathy: Clinical and Hematologic Therapy Response and Hints on New Therapeutic Targets. Neurol Neuroimmunol Neuroinflamm **10(4)**: e200122  
DOI: [10.1212/NXI.0000000000200122](https://doi.org/10.1212/NXI.0000000000200122)

**Doneddu P E et al., 2023:** A diagnostic score for anti-myelin-associated-glycoprotein neuropathy or chronic inflammatory demyelinating polyradiculoneuropathy in patients with anti-myelin-associated-glycoprotein antibody. E. Eur J Neurol **30(2)**: 501-510  
DOI: [10.1111/ene.15296](https://doi.org/10.1111/ene.15296)

**Doneddu P E et al. (Italian CIDP Database study group), 2023:** Unclassified clinical presentations of chronic inflammatory demyelinating polyradiculoneuropathy. J Neurol Neurosurg Psychiatry **94(8)**: 614-621  
DOI: [10.1136/jnnp-2022-331011](https://doi.org/10.1136/jnnp-2022-331011)

**Sato R et al., 2023:** Autocrine TNF- $\alpha$  Increases Penetration of Myelin-Associated Glycoprotein Antibodies Across the Blood-Nerve Barrier in Anti-MAG Neuropathy. Neurol Neuroimmunol Neuroinflamm **10(3)**: e200086  
DOI: [10.1212/NXI.0000000000200086](https://doi.org/10.1212/NXI.0000000000200086)

**Silsby M et al., 2023:** Upper and lower limb tremor in Charcot-Marie-Tooth neuropathy type 1A and the implications for standing balance. Eur J Neurol **30(4)**: 1059-1068  
DOI: [10.1007/s00415-023-12124-z](https://doi.org/10.1007/s00415-023-12124-z)

**Stino A M et al., 2023:** Anti-myelin-associated glycoprotein neuropathy: Where do we stand? Muscle Nerve **68(6)**: 823-832  
DOI: [10.1002/mus.27954](https://doi.org/10.1002/mus.27954)

**Amaador K et al., 2022:** Serum neurofilament light chain, contactin-1 and complement activation in anti-MAG IgM paraprotein-related peripheral neuropathy. J Neurol **269(7)**: 3700-3705  
DOI: [10.1007/s00415-022-10993-4](https://doi.org/10.1007/s00415-022-10993-4)

**Dorcet G et al., 2022:** Case Report: Presence of Anti-MAG in the CSF Can Be Associated With a Neurodegenerative Process With Frontal Involvement. Neurol **13**: 847798  
DOI: [10.3389/fneur.2022.847798](https://doi.org/10.3389/fneur.2022.847798)

**Nivet T et al., 2022:** Immunochemotherapy versus rituximab in anti-myelin-associated glycoprotein neuropathy: A report of 64 patients. Br J Haematol **198(2)**: 298-306  
DOI: [10.1111/bjh.18202](https://doi.org/10.1111/bjh.18202)

**Tozza S et al., 2022:** Value of Antibody Determinations in Chronic Dysimmune Neuropathies. Brain Sci **13(1)**: 37  
DOI: [10.3390/brainsci13010037](https://doi.org/10.3390/brainsci13010037)

**Trentinaglia M et al., 2022:** Peripheral neuropathies during the COVID-19 pandemic: is there a relation?

Immunol Res **70(3)**: 408-413

DOI: [10.1007/s12026-022-09272-1](https://doi.org/10.1007/s12026-022-09272-1)

**Vallat J M et al., 2022:** Widening of myelin lamellae in polyneuropathy with immunoglobulin-M monoclonal gammopathy, without activity against myelin-associated glycoprotein, responsive to treatment. *Neuromuscul Disord* **32(8)**: 678-681

DOI: [10.1016/j.nmd.2022.05.001](https://doi.org/10.1016/j.nmd.2022.05.001)

**Askari E et al., 2021:** Waldenström's Macroglobulinemia: An Exploration into the Pathology and Diagnosis of a Complex B-Cell Malignancy. *J Blood Med* **30(12)**: 795-807

DOI: [10.2147/JBM.S267938](https://doi.org/10.2147/JBM.S267938)

**Hänggi P et al., 2021:** Decrease in Serum Anti-MAG Autoantibodies Is Associated With Therapy Response in Patients With Anti-MAG Neuropathy: Retrospective Study. *Neurol Neuroimmunol Neuroinflamm* **10;9(1)**: e1109

DOI: [10.1212/NXI.0000000000001109](https://doi.org/10.1212/NXI.0000000000001109)

**Latov N, 2021:** Antibody testing in neuropathy associated with anti-Myelin-Associated Glycoprotein antibodies: where we are after 40 years. *Expert Rev Clin Immunol* **17(12)**: 1269-1281

DOI: [10.1080/1744666X.2021.2002147](https://doi.org/10.1080/1744666X.2021.2002147)

**Matà S et al., 2021:** Polyneuropathy and monoclonal gammopathy of undetermined significance (MGUS); update of a clinical experience. *J Neurol Sci* **423**: 117335

DOI: [10.1016/j.jns.2021.117335](https://doi.org/10.1016/j.jns.2021.117335)

**Steck A J, 2021:** Anti-MAG neuropathy: From biology to clinical management. *J Neuroimmunol* **361**: 577725

DOI: [10.1016/j.jneuroim.2021.577725](https://doi.org/10.1016/j.jneuroim.2021.577725)

**Vallat J M, et al., 2021:** The Wide Spectrum of Pathophysiologic Mechanisms of Paraproteinemic Neuropathy. *Neurology* **96(5)**: 214-225

DOI: [10.1212/WNL.00000000000011324](https://doi.org/10.1212/WNL.00000000000011324)

**Aliu B et al., 2020:** Selective inhibition of anti-MAG IgM autoantibody binding to myelin by an antigen-specific glycopolymer; *Journal of Neurochemistry (JNC)* **154**: 486-501.

DOI: [10.1111/jnc.15021](https://doi.org/10.1111/jnc.15021) PMID: **32270492**

**Boscarino M et al., 2020:** Spinal Cord Impairment in anti-MAG Neuropathy: Evidence from Somato-sensory Evoked Potentials. *Brain Sci.* **10(282)**: 1-10

DOI: [10.3390/brainsci10050282](https://doi.org/10.3390/brainsci10050282)

**Castellani F et al., 2020:** The Bruton tyrosine kinase inhibitor ibrutinib improves anti-MAG antibody polyneuropathy. *Neurol Neuroimmunol Neuroinflamm* **13;7(4)**:e720

DOI: [10.1212/NXI.0000000000000720](https://doi.org/10.1212/NXI.0000000000000720) PMID: **32010046** PMCID: PMC6971200

**Colchester N T H et al., 2020:** Chemoimmunotherapy with rituximab, cyclophosphamide and prednisolone in IgM paraproteinaemic neuropathy: evidence of sustained improvement in electrophysiological, serological and functional outcomes. *Haematologica* **2020** [Epub ahead of print]

DOI: [10.3324/haematol.2019.243139](https://doi.org/10.3324/haematol.2019.243139)

**Doneddu P E (Italian CIDP Database study group) et al., 2020:** Frequency of diabetes and other comorbidities in chronic inflammatory demyelinating polyradiculoneuropathy and their impact on clinical presentation and response to therapy. *J Neurol Neurosurg Psychiatry* **91(10)**: 1092-1099

DOI: [10.1136/JNNP-2020-323615](https://doi.org/10.1136/JNNP-2020-323615)

**Gastaldi M et al., 2020:** Autoantibody Diagnostics in Neuroimmunology: Experience From the 2018 Italian Neuroimmunology Association External Quality Assessment Program. *Front Neurol.* **10:138510(1385)**: 1 -12

PMCID: [PMC6971200](https://pubmed.ncbi.nlm.nih.gov/326971200/)

**Liberatore G et al., 2020:** Sensitivity and specificity of a commercial ELISA test for anti-MAG antibodies in patients with neuropathy. *J Neuroimmunol* **345**:577288.

DOI: [10.1016/j.jneuroim.2020.577288](https://doi.org/10.1016/j.jneuroim.2020.577288) PMID: **32544754**

**Neil J et al., 2020:** Native vs deglycosylated IgM anti-MAG neuropathy: Correlation with clinical status – Study of 10 cases. *J Neuroimmunol.* **15;339**:577094.

DOI: [10.1016/j.jneuroim.2019.577094](https://doi.org/10.1016/j.jneuroim.2019.577094) PMID: **31756640**

**Matà S et al., 2019:** Anti-MAG IgM: differences in antibody tests and correlation with clinical findings. *Neurol Sci* **41(2)**: 365-372  
DOI: [10.1007/s10072-019-04089-7](https://doi.org/10.1007/s10072-019-04089-7)

**Pascual-Goñi E et al., 2019:** Clinical and laboratory features of anti-MASG neuropathy without monoclonal gammopathy. *Sci Rep* **16**; 9(1): 6155  
DOI: [10.1038/s41598-019-42545-8](https://doi.org/10.1038/s41598-019-42545-8)

**Briani C et al., 2018:** Obinuzumab, a new anti-CD20 antibody, and Chlorambucil are active and effective in anti-MAG antibody polyneuropathy. *Eur J Neurol* **26(2)**: 371-375  
DOI: [10.1111/ene.13838](https://doi.org/10.1111/ene.13838)

**Falzone YM et al., 2018:** Functioning and quality of life in patients with neuropathy associated with anti-MAG antibodies; *J Neurol*. **265(12)**: 2927-2933  
DOI: [10.1007/s00415-018-9081-7](https://doi.org/10.1007/s00415-018-9081-7)

**Garg N et al., 2018:** Anti-MAG neuropathy: role of IgM antibodies, the paranodal junction and juxtaparanodal potassium channels. *Clin Neurophysiol* **129(10)**: 2162-2169  
DOI: [10.1016/j.clinph.2018.07.021](https://doi.org/10.1016/j.clinph.2018.07.021)

**Svahn J et al., 2018:** Anti-MAG antibodies in 202 patients: clinicopathological and therapeutic features. *J Neurol Neurosurg Psychiatry* **89(5)**: 499-505  
DOI: [10.1136/jnnp-2017-316715](https://doi.org/10.1136/jnnp-2017-316715)

**Campagnolo M et al., 2017:** IgM MGUS and Waldenstrom-associated anti-MAG neuropathies display similar response to rituximab therapy. *J Neurol Neurosurg Psychiatry* **88(12)**: 1094-1097  
DOI: [10.1136/jnnp-2017-315736](https://doi.org/10.1136/jnnp-2017-315736)

**D'Sa S et al., 2017:** Investigation and Management of IgM and Waldenström-associated peripheral neuropathies: recommendations from the IWWM-8 consensus panel. *Brit J Haematol* **176(5)**: 728-742  
DOI: [10.1111/bjh.14492](https://doi.org/10.1111/bjh.14492)

**Nobile-Orazio E et al., 2017:** Comparing treatment options for chronic inflammatory neuropathies and choosing the right treatment plan. *Expert Review of Neurotherapeutics* **17(8)**: 755-765.  
DOI: [10.1080/14737175.2017.1340832](https://doi.org/10.1080/14737175.2017.1340832)

**Lozeron P et al., 2016:** Is distal motor/or sensory demyelination a distinctive feature of anti-MAG neuropathy? *J. Neurol* **263**: 1761-1770  
DOI: [10.1007/s00415-016-8187-z](https://doi.org/10.1007/s00415-016-8187-z)

**Magy L et al., 2015:** Heterogeneity of Polyneuropathy Associated with Anti-MAG Antibodies. *J Immunol Res*; **2015**: 450391  
DOI: [10.1155/2015/450391](https://doi.org/10.1155/2015/450391)

**Stork A C J et al., 2014:** Prevalence, specificity and functionality of anti-ganglioside antibodies in neuropathy associated with IgM monoclonal gammopathy. *J Neuroimmunol* **268(1-2)**: 89-94  
DOI: [10.1016/j.jneuroim.2014.01.012](https://doi.org/10.1016/j.jneuroim.2014.01.012)

**Willison H J et al., 2011:** Use of antibody testing in nervous system disorders. *European Handbook of Neurological Management: volume 1, 2<sup>nd</sup> edition; chapter 6*: 75-80  
DOI: [10.1002/9781444328394.ch6](https://doi.org/10.1002/9781444328394.ch6)

**Kuijf M et al., 2009:** Detection of anti-MAG antibodies in polyneuropathy associated with IgM monoclonal gammopathy. *Neurology* **73(9)**: 688-695  
DOI: [10.1212/WNL.0b013e3181b59a80](https://doi.org/10.1212/WNL.0b013e3181b59a80)

**Renaud S et al., 2003:** Rituximab in the treatment of polyneuropathy associated with anti-MAG antibodies. *Muscle Nerve* **27(5)**: 611-615.  
DOI: [10.1002/mus.10359](https://doi.org/10.1002/mus.10359)

#### Posters:

**Castellani F et al., 2019:** Ibrutinib in Neuropathy with anti-Myelin-Associated Glycoprotein (MAG) Antibody. Poster presented at **2019** "Peripheral Nerve Society" (PNS) Annual Meeting in Genova (IT)

**Greco N et al., 2019:** Small Fiber involvement in anti-MAG demyelinating neuropathy – data from a small cohort. Poster presented at **2019** "Peripheral Nerve Society" (PNS) Annual Meeting in Genova (IT)



**Herrendorff R et al., 2018:** Novel treatment opportunity for anti-myelin-associated glycoprotein neuropathy. Poster presented at **2018** "Peripheral Nerve Society" (PNS) Annual Meeting in Baltimore, MY (USA)

**Camdessanché JP et al., 2017:** Therapeutic Management in 202 Patients. Poster presented at **2017** "Peripheral Nerve Society" (PNS) Annual Meeting in Sitges (ES)

**Delmont E et al., 2017:** Value of anti-HNK-1 Antibodies in anti-MAG Neuropathies: an analysis of 144 sera. Poster presented at **2017** "Peripheral Nerve Society" (PNS) Annual Meeting in Sitges (ES)

**Neil J et al., 2017:** Do anti-MAG titers have a good correlation with clinical status in IgM anti-MAG Neuropathy? Poster presented at **2017** "Peripheral Nerve Society" (PNS) Annual Meeting in Sites (ES)

Further literature citing anti-MAG Antibodies ELISA IVD test by BÜHLMANN:

**Baron M et al., 2017:** Plasma exchanges for acute neurological deterioration in patients with IgM anti-myelin-associated glycoprotein (anti-MAG) neuropathy. *Journal of Neurology* **264(6)**: 1132-1135  
DOI: [10.1007/s00415-017-8502-3](https://doi.org/10.1007/s00415-017-8502-3)

**Campagnolo M et al., 2017:** IgM MGUS and Waldenstrom-associated anti-MAG neuropathies display similar response to rituximab therapy. *J Neurol Neurosurg Psychiatry* **88(12)**: 1094-1097  
DOI: [10.1136/jnnp-2017-315736](https://doi.org/10.1136/jnnp-2017-315736)

**Doneddu P E et al., 2017:** Deterioration of tremor after treatment with rituximab in anti-MAG neuropathy (Letter to the Editor). *Journal of the Neurological Sciences* **373**: 344-345  
DOI: [10.1016/j.jns.2016.12.029](https://doi.org/10.1016/j.jns.2016.12.029)

**Gazzola S et al., 2017:** Predictive factors of efficacy of rituximab in patients anti-MAG neuropathy. *Journal of the Neurological Sciences* **377**: 144-148  
DOI: [10.1016/j.jns.2017.04.015](https://doi.org/10.1016/j.jns.2017.04.015)

**Gesquière-Dando A et al., 2017:** Are electrophysiological features related to disability in patients with anti-MAG neuropathy? *Clinical Neurophysiology* **47**: 75-81  
DOI: [10.1016/j.neucli.2017.01.002](https://doi.org/10.1016/j.neucli.2017.01.002)

**Fatehi F et al., 2017:** Motor unit number index (MUNIX) in patients with anti-MAG neuropathy. *Clinical Neurophysiology* **128(7)**: 1264-1269  
DOI: [10.1016/j.clinph.2017.04.022](https://doi.org/10.1016/j.clinph.2017.04.022)

**Herrendorff R et al., 2017:** Selective in vivo removal of pathogenic anti-MAG autoantibodies, an antigenspecific treatment option for anti-MAG neuropathy. *PNAS* May 2, 2017 **114(18)**: E3689-E3698  
DOI: [10.1073/pnas.1619386114](https://doi.org/10.1073/pnas.1619386114)

**Ferfoglia R I et al., 2016:** Long-term efficacy of rituximab in IgM anti-myelin-associated glycoprotein neuropathy: RIMAG follow-up study. *J Peripher Nerv Syst* **21(1)**: 10-14  
DOI: [10.1111/jns.12156](https://doi.org/10.1111/jns.12156)

**Gomez A and Hoffman J E, 2016:** Anti Myelin-Associated-Glycoprotein Antibody Peripheral Neuropathy Response to Combination Chemoimmunotherapy with Bendamustine/Rituximab in a Patient With Biclonal IgM  $\kappa$  and IgM  $\lambda$ : Case Report and Review of the Literature. *Clin Lymphoma Myeloma Leuk* **16(7)**: e101-108.  
DOI: [10.1016/j.clml.2016.04.004](https://doi.org/10.1016/j.clml.2016.04.004)

**Stork A C J et al., 2016:** Classical and lectin complement pathway activity in polyneuropathy associated with IgM monoclonal gammopathy. *J Neuroimmunol* **290**: 76-79  
DOI: [10.1016/j.jneuroim.2015.11.010](https://doi.org/10.1016/j.jneuroim.2015.11.010)

**Campagnolo M et al., 2015:** Polyneuropathy with anti-sulfatide and anti-MAG antibodies: clinical, neurophysiological, pathological features and response to treatment. *J Neuroimmunol* **281**: 1-4  
DOI: [10.1016/j.jneuroim.2015.02.009](https://doi.org/10.1016/j.jneuroim.2015.02.009)

**Bridel C et al., 2014:** Multifocal motor neuropathy with high titers of anti-MAG antibodies. *J Peripher Nerv Syst* **19(2)**: 180-182  
DOI: [10.1111/jns5.12069](https://doi.org/10.1111/jns5.12069)

**Sala E et al., 2014:** Acute neurological worsening after Rituximab treatment in patients with anti-MAG neuropathy. *J Neurol Sci* **345(1-2)**: 224-227  
DOI: [10.1016/j.jns.2014.07.055](https://doi.org/10.1016/j.jns.2014.07.055)

- Stork A C J et al., 2014:** Clinical phenotype of patients with neuropathy associated with monoclonal gammopathy: a comparative study and a review of the literature. *J Neurol* **261(7)**: 1389-1404  
DOI: [10.1007/s00415-014-7354-3](https://doi.org/10.1007/s00415-014-7354-3)
- Hospital M A et al., 2013:** Immunotherapy-based regimen in anti-MAG neuropathy: results in 45 patients. *Haematologica* **98(12)**: e155-157  
DOI: [10.3324/haematol.2013.087213](https://doi.org/10.3324/haematol.2013.087213)
- Piscosquito G et al., 2013:** Coexistence of Charcot-Marie-Tooth disease type 1A and anti-MAG neuropathy. *J Peripher Nerv Syst* **18(2)**: 185-188  
DOI: [10.1111/jns5.12029](https://doi.org/10.1111/jns5.12029)
- Stork A C J et al., 2013:** Rapid worsening of IgM anti-MAG demyelinating polyneuropathy during rituximab treatment. *J Peripher Nerv Syst* **18(2)**: 189-192  
DOI: [10.1111/jns5.12018](https://doi.org/10.1111/jns5.12018)
- Maurer M A et al., 2012:** Rituximab induces sustained reduction of pathogenic B cells in patients with peripheral nervous system autoimmunity. *J Clin Invest* **122(4)**:1393-1402  
DOI: [10.1172/JCI58743](https://doi.org/10.1172/JCI58743)
- Mostafa G A et al., 2012:** Reduced serum concentrations of 25-hydroxy vitamin D in children with autism: relation to autoimmunity. *J Neuroinflammation* **17(9)**: 201  
DOI: [10.1186/1742-2094-9-201](https://doi.org/10.1186/1742-2094-9-201)
- Pihan M et al., 2012:** [Neuropathies associated with monoclonal IgM anti-MAG antibodies]. *Rev Med Interne* **33(12)**: 686-692  
DOI: [10.1016/j.revmed.2012.05.009](https://doi.org/10.1016/j.revmed.2012.05.009)
- Delmont E et al., 2011:** Treatment with rituximab in patients with polyneuropathy with anti-MAG antibodies. *J Neurol* **258(9)**: 1717-1719  
DOI: [10.1007/s00415-011-5994-0](https://doi.org/10.1007/s00415-011-5994-0)
- Gruson B et al., 2011:** Long-term response to rituximab and fludarabine combination in IgM anti-myelin-associated glycoprotein neuropathy. *J Peripher Nerv Syst* **16(3)**: 180-185  
DOI: [10.1111/j.1529-8027.2011.00343.x](https://doi.org/10.1111/j.1529-8027.2011.00343.x)
- Jurici S et al., 2011:** An Autopsy Case of Amyotrophic Lateral Sclerosis with Waldenstrom Macroglobulinemia and Anti-MAG Gammopathy. *Case Rep Neurol* **3(3)**: 294-400  
DOI: [10.1159/000335004](https://doi.org/10.1159/000335004)
- Larue S et al., 2011:** Non-anti-MAG DADS neuropathy as a variant of CIDP: clinical, electrophysiological, laboratory features and response to treatment in 10 cases. *Eur J Neurol* **18(6)**: 899-905  
DOI: [10.1111/j.1468-1331.2010.03312.x](https://doi.org/10.1111/j.1468-1331.2010.03312.x)
- Matà S et al., 2011:** Anti-myelin associated glycoprotein antibodies recognize HNK-1 epitope on CNS. *J Neuroimmunol* **236(1-2)**: 99-105  
DOI: [10.1016/j.jneuroim.2011.05.002](https://doi.org/10.1016/j.jneuroim.2011.05.002)
- Matà S et al., 2011:** IgM monoclonal gammopathy-associated neuropathies with different IgM specificity. *Eur J Neurol* **18(8)**: 1067-1073  
DOI: [10.1111/j.1468-1331.2010.03345.x](https://doi.org/10.1111/j.1468-1331.2010.03345.x)
- Théaudin M et al., 2011:** Short and long-term effect of IVIg in demyelinating neuropathy associated with MGUS, experience of a monocentric study. *Rev Neurol (Paris)* **167(12)**: 897-904  
DOI: [10.1016/j.neurol.2011.04.005](https://doi.org/10.1016/j.neurol.2011.04.005)
- Zara G et al., 2011:** Neurophysiological and clinical responses to rituximab in patients with anti-MAG polyneuropathy. *Clin Neurophysiol* **122(12)**: 2518-2522  
DOI: [10.1016/j.clinph.2011.05.015](https://doi.org/10.1016/j.clinph.2011.05.015)
- Jaskowsky T D et al., 2007:** Further comparisons of assays for detecting MAG IgM autoantibodies. *J Neuroimmunol* **187(1-2)**: 175-178  
DOI: [10.1016/j.jneuroim.2007.04.015](https://doi.org/10.1016/j.jneuroim.2007.04.015)
- Caudie C et al., 2006:** [Diagnostic value of autoantibodies to MAG by ELISA Bühlmann in 117 immune-mediated peripheral neuropathies associated with monoclonal IgM to SGPG/SGLPG]. *Ann Biol Clin* **64(4)**: 353-359  
PMID: [16829480](https://pubmed.ncbi.nlm.nih.gov/16829480/)

**Renaud S et al., 2006:** High-dose rituximab and anti-MAG-associated polyneuropathy. *Neurology* **66(5)**: 742-744  
DOI: [10.1212/01.wnl.0000201193.00382.b3](https://doi.org/10.1212/01.wnl.0000201193.00382.b3)

**Steck A et al., 2006:** Anti-myelin-associated glycoprotein neuropathy. *Curr Opin Neurol* **19(5)**: 458-463  
DOI: [10.1097/01.wco.0000245368.36576.0d](https://doi.org/10.1097/01.wco.0000245368.36576.0d)

**Kvarnström M et al., 2002:** Myelin protein P0-specific IgM producing monoclonal B cell lines were established from polyneuropathy patients with monoclonal gammopathy of undetermined significance (MGUS).  
*Clin Exp Immunol* **127(2)**: 255-262  
DOI: [10.1046/j.1365-2249.2002.01739.x](https://doi.org/10.1046/j.1365-2249.2002.01739.x)

## anti-SGPG Autoantibodies ELISA IVD test by BÜHLMANN - 4 References

**Herrendorff R et al., 2017:** Selective *in vivo* removal of pathogenic anti-MAG autoantibodies, an antigen specific treatment option for anti-MAG neuropathy. *PNAS* May 2, 2017 **114(18)**: E3689-E3698  
DOI: [10.1073/pnas.1619386114](https://doi.org/10.1073/pnas.1619386114)

**Bridel C et al., 2014:** Multifocal motor neuropathy with high titres of anti-MAG antibodies.  
*J Peripher Nerv Syst* **19(2)**: 180-182  
DOI: [10.1111/jns5.12069](https://doi.org/10.1111/jns5.12069)

**Kuijf M et al., 2009:** Detection of anti-MAG antibodies in polyneuropathy associated with IgM monoclonal gammopathy.  
*Neurology* **73(9)**: 688-695  
DOI: [10.1212/WNL.0b013e3181b59a80](https://doi.org/10.1212/WNL.0b013e3181b59a80)

**Caudie C et al., 2007:** [Diagnostic value of the anti-IgM SGPG Elisa (BÜHLMANN Laboratories AG) in 147 sera with a monoclonal IgM anti-MAG/SGPG antibody-associated neuropathy]. *Ann Biol Clin (Paris)* **65(4)**: 369-375  
PMID: [17627917](https://pubmed.ncbi.nlm.nih.gov/17627917/)



BÜHLMANN Laboratories AG Phone +41 61 487 12 12  
Baselstrasse 55 Contact [support@buhlmannlabs.ch](mailto:support@buhlmannlabs.ch)  
4124 Schönenbuch [info@buhlmannlabs.ch](mailto:info@buhlmannlabs.ch)  
Switzerland [www.buhlmannlabs.ch](http://www.buhlmannlabs.ch)

LLB064ML-08E